The combination of the PIM‐2 inhibitor SMI‐16a and the PARP1 inhibitor ABT888 shows a synergistic effect in inducing DNA damage in MM cells, which results in increased MICA expression. The gene discussed is PARP1; the disease is Miyoshi myopathy.